Prostrakan Share Discussion Threads

[zulu002] 02/7/2008 12:53

Novaquest is the strategic partnering arm of the US group Quintiles Transnational, the biggest recruiter of pharma reps in the US, employing around 45,000 sales professionals, working for companies like GSK, AZ, Pfizer etc If you are going to launch a new product in the States, a partnership with Novaquest should bring the expertise & the experience that is required.

[zulu002] 01/7/2008 16:23

From The Sunday Times

June 29, 2008

ProStraken poised for US cancer patch breakthrough

The Borders drug firm next week hear if it has won American approval for its anti-nausea treatment


Borders drug firm ProStrakan could be on the verge of a big breakthrough in the US if it wins approval next week for its anti-nausea cancer patch Sancuso

The US Food and Drugs Administration will decide in the week beginning July 7 whether to approve Sancuso. Last month it said it had no outstanding issues and was in "labelling discussions".

If it gets the go-ahead, ProStrakan will trigger a deal with NovaQuest to recruit a 75-strong sales team and launch Sancuso in America later this year. NovaQuest specialises in strategic sales partnerships with biotech companies. ProStrakan already has a US management team in place.

Sancuso, which would be the company's first product in the important US market, could generate $100m (£50m) of income annually in the States alone. If the patch receives EU approval, the company plans to launch it in Europe early next year.

The market in the US for the three drugs which ProStrakan hopes to market - Sancuso, Fortigel and Cellegesic - is estimated to be worth between $400m and $500m.

Last week, the company received approval to sell cancer painkiller Abstral in Europe, a move which could double its European revenues.

One analyst said 2008 is shaping up to be Galashiels-based ProStrakan's "coming of age". Broker Piper Jaffray said last week that ProStrakan was on the verge of "an acceleration of growth". Its shares ended last week on 79.5p, just below its highest price in the last 12 months of 85p.

[zulu002] 01/7/2008 15:56

Landsbanki has a "buy" investment rating on ProStrakan and a target price of 123 pence a share.

[password] 01/7/2008 08:22

bdawes and stockcontroler - the impact of testosterone replacement on insulin sensitivity has been known for years, this is not cutting edge stuff.

The US market getting tougher, generic usage increasing, unless this management get to grips with that and price right it will be a poor show

Sancuso is up against a range of fentanyl delivery systemd as well as competitor morphine type drugs, again pricing/health outcome support is now almost mandatory, not sure the management really grasp this

[zulu002] 30/6/2008 11:31

1,306,949 buys v 37,504 sells on Friday, following a positive opinion from CHMP regarding Abstral.

News still to come re: Sancuso.

[cymbelline] 19/6/2008 23:23

I meant today in response to the news. At the time I posted there was one trade on afn of 750 shares, which is a bit less than you'd expect if the market was impressed, even if it had been a buy. By close the total traded on both LSE and Plus market together was only 16,663, with the vast majority sells. So notalot of interest and most of what there was was negative.

25% in 3 weeks is pretty good going, it's overbought and badly in need of a pullback. It's fine to let the trend be your friend but if you let it call all the shots it's likely to let you down now and again.

[cjaj2] 19/6/2008 12:26

Between May 28th and June 19th (3 weeks) the price has gone from 60p to 80p. How is that 'no interest' ?

Lets hope the trend is our friend on this one.

[cymbelline] 18/6/2008 08:33

It's testosterone reduction therapy we need on these bbs. :)

Taken profits on this, can't see much more upside technically and there seems to be absolutely no interest even with positive news.

[sheeneqa] 09/6/2008 16:21

Looks like all is looking positive for next month.....

[dak] 23/5/2008 11:52

Disappointing rise considering the announcement

[sheeneqa] 19/5/2008 09:08

ProStrakan signs licence, supply agreement for sale of Xomolix in CEE, Austria




LONDON (Thomson Financial) - ProStrakan Group Plc. said it has signed a
licence and supply agreement with Torrex Chiesi Pharma GmbH for the sale of
post-operative nausea treatment drug Xomolix in Central and Eastern Europe (CEE)
and Austria.
Under the terms of the agreement, the pharmaceutical company said it will
exclusively supply Xomolix to Torrex in CEE and Austria for 10 years and will
receive an undisclosed royalty rate on sales generated by Torrex.
[e-mail]

[chatterbox] 09/5/2008 10:18

Any thoughts on this share - in times today

[password] 18/4/2008 16:06

Looks like another has made it before Prostrakan

FRAZER, Pa. and MAISONS-ALFORT, France, April 14, 2008 /PRNewswire-FirstCall/ -- Cephalon, Inc. announced today that the European Commission has granted marketing authorization for Effentora(TM), a buccal tablet formulation of fentanyl. EFFENTORA is indicated for the treatment of breakthrough cancer pain (BTCP) in adult patients who are already receiving maintenance opioid therapy for chronic pain. The approval allows Cephalon to market EFFENTORA in the 27 member states of the European Union (EU), as well as Iceland and Norway.



Breakthrough cancer pain, an often debilitating condition, is characterized by its rapid onset, moderate-to-severe intensity, and its relatively short duration. Research studies have demonstrated that an estimated 51-89 percent of patients with cancer who are taking around-the- clock opioid therapy for their underlying persistent pain will experience breakthrough pain.

[grimraider] 28/3/2008 18:57

Hi BB

Agree, sector looks a bit grim, one company which seems to be moving up after a long downturn is in Media buying and Market research - Aegis. Some ongoing rumour of a takeover by French (Bollore of Havas group) may be too late to get in with any chance of significant gains.

Pharma market appears to be moving towards old soviet block/china/india with all the associated problems, renegotiation of pharma pricing here and increasing FDA constraints (MORE DRUGS BEING REASSESSED RE CARDIOVASCULAR SIDE EFFECTS) and costs make Europe and US look bad bets. Looks like the time for small volume high price specialist pharmaceuticals rather than blockbusters has arrived (I dont mean me too branded generics. Major Pharma downsizing - Wyeth announced cuts in US of 1,200 sales reps as of Monday! Little positive news, suspect Pharma investing will be risker than normal!

[password] 28/3/2008 08:17

BracknellBoy, yes, cost control seems to be an alien concept to this management team. With growing pressures on US healthcare, am regretting buying in, as dont see much in the way of a return even on a 2 to 3 year horizone.

[jayesbee] 27/3/2008 18:51

BB,

re: mdx punching its weight - even with the proposed takover talks you think it will remain at this level?
i take it you are not invested?

[bracknellboy] 27/3/2008 18:46

Grimrader, look at those figures. £45m of revs and they still are losing £17m per year. There is no way the business will climb unless there is a rapid change in fortunes, possibly with the US product launches.

Compare this performance with others in the sector and it is terrible. Sinclair is down, Prostrakan is down. The only one punching its weight is Meldex but can;t see that going much higher when you compare it with others.

[grimraider] 26/3/2008 16:48

Snouts in trough again and share price half what it was with no sign of any upward movement

[waldron] 13/3/2008 07:55

Prostrakan full year operating losses narrow; breakeven predicted in 2009




LONDON (Thomson Financial) - Prostrakan PLC, the Scottish specialty
pharmaceutical company, narrowed its full year operating losses to 17.7 mln stg,
down from 18.3 mln, as a result of organic sales growth and product launches,
while the company says it now has the funding in place to carry it through to
breakeven in 2009.
Group sales for the year were up 19 pct to 45.6 mln stg, compared with 38.5
mln, in 2006. Loss per share was 8.6 pence, down 41 pct on last year, while the
company's cash position was 24.5 mln stg, with a further 30 mln available from
an agreed debt facility: the company has a 50 mln stg debt facility, of which
15.7 mln had been used during the year, Prostrakan said.
The company specialises in a variety of pain relief products and also
markets the Tostran transdermal testosterone gel in Europe, where sales grew by
256 pct last year, Prostrakan said.
Prostrakan CEO Wilson Totten said: "2008 is set to be a transformational
year, with regulatory approvals of key products anticipated in both Europe and
the US and important results due on two further products in Phase III US trials.
The Company is strongly funded and remains on track to achieve its target of
break-even during 2009."


[e-mail]
jh1/slm

[grimraider] 03/3/2008 20:08

Unusually quiet even for this one. At least seems to have bottomed out at a higher level than last time. US market looking more challenging even with the agreed support

[grimraider] 03/3/2008 20:08

Unusually quiet even for this one. At least seems to have bottomed out at a higher level than last time. US market looking more challenging even with the agreed support